| Document |
Document Title |
|
WO/2014/145116A2 |
Disclosed herein are alkyl-heteroaryl substituted quinone derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing diso...
|
|
WO/2014/136807A1 |
Provided is a cell-death inhibitor including, as an active ingredient thereof, a compound represented by formula (1), and/or a compound represented by formula (2). The cell-death inhibitor exhibits high cell-death inhibition activity.
|
|
WO/2014/136808A1 |
Provided is a cell-death inhibitor including, as an active ingredient thereof, a compound represented by formula (1), and/or a compound represented by formula (2). The cell-death inhibitor exhibits high cell-death inhibition activity.
|
|
WO/2014/135423A1 |
The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of...
|
|
WO/2014/131572A1 |
Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.
|
|
WO/2014/132971A1 |
A fused heterocyclic compound or an N-oxide thereof represented by formula (1) has an excellent control effect on pests. [In the formula: A1 represents N or the like; A2 represents NR6 or the like; A3 represents CR12 or the like; R1 repr...
|
|
WO/2014/132972A1 |
A fused heterocyclic compound or an N-oxide thereof represented by formula (1) has an excellent control effect on pests. [In the formula: A1 represents NR8 or the like; A2 and A3 represent N or the like; Q represents O or S; R1 represent...
|
|
WO/2014/123239A1 |
Provided is a long-lifetime organic light-emitting element having a good device lifetime characteristic. The organic light-emitting device includes: a pair of electrodes; and an organic compound layer placed between the pair of electrode...
|
|
WO/2014/123203A1 |
Provided is a compound having PTP-1B inhibitory activity that is excellent as a drug, or a pharmaceutically acceptable salt thereof. A compound represented by general formula (I) (in the formula, each symbol means the same as in the spec...
|
|
WO/2014/122811A1 |
Provided is an easy method (coupling method) capable of easily synthesizing a compound group in which aromatic molecules and aromatic molecules are coupled, a compound group in which aromatic molecules and alkene molecules are coupled, a...
|
|
WO/2014/122303A1 |
The present invention provides compounds with anti-fungal activity useful for treatment or prevention of fungal infections in human beings or plants. The antifungal compounds are inhibitors of glucan synthase and have the formula (I) (I)...
|
|
WO/2014/121634A1 |
A compound in formula I, and a preparation method and use thereof. The compound has a function of sensing and regulating a bacterial colony, and can be used for prevention and/or treatment of related diseases caused by bacterial infection.
|
|
WO/2014/119947A1 |
The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a CETP inhibitory effect that increase...
|
|
WO/2014/116593A1 |
The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.
|
|
WO/2014/112646A1 |
The present invention addresses the problem of providing a compound having a selective inhibitory activity on LAT-1 that can be expressed in a tumor cell at a high level. The present invention provides: a compound represented by formula ...
|
|
WO/2014/111953A1 |
The present invention relates to a novel process for the preparation of anacetrapib. The present invention also relates to novel intermediate or its salt and its use in the preparation of anacetrapib.
|
|
WO/2014/109296A1 |
Disclosed is a compound represented by formula (1) or a salt thereof. In formula (1): X represents a residue of a compound having an activity to bind to at least one member selected from the group consisting of amyloid β protein, a tau ...
|
|
WO/2014/110491A1 |
Prodrugs of treprostinil are provided which can be used in the treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable...
|
|
WO/2014/108525A1 |
A novel process for the preparation of a fluorolactone derivative of the formula (I) and of its acylated derivative of formula (V) wherein R1 stands for a hydroxy protecting group is described. The acylated fluorolactones of formula (V),...
|
|
WO/2014/106310A1 |
The invention discloses a halogen-containing optically active oxazolidinone derivative and a preparation method therefor. The structural formula of the compound is shown as formula I. In the present invention, N-bromosuccinimide is used ...
|
|
WO/2014/101064A1 |
Disclosed is a method for preparing linezolid crystalline form I. Specifically, the preparation method of the present invention comprises the steps of: (1) mixing linezolid crude product with a first solvent, filtering, and collecting th...
|
|
WO/2014/104407A1 |
Disclosed is a compound represented by formula (1): wherein A1 represents N(O)p or CH; A2 represents N(O)q; R1 represents a trifluoromethyl group, a halogen atom or a hydrogen atom; R2 represents a C1-C3 perfluoroalkyl group, p represent...
|
|
WO/2014/095753A1 |
Polymer, comprising i) at least one oxazoline according to formula wherein R1, R2, R3 and R4 independently denote a hydrogen atom, a halogen atom, an alkyl group, an aralkyl group, a phenyl group, or a substituted phenyl group, and R5 de...
|
|
WO/2014/099836A1 |
Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treatin...
|
|
WO/2014/100438A1 |
The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhib...
|
|
WO/2014/086734A1 |
The invention relates to N-(isoxazol-3-yl)-aryl-carboxylic acid amides and use thereof as herbicides. In formula (I), A stands for N or C-Y. R, R', V, X, Y, and Z stand for groups such as hydrogen, halogen, and organic groups such as sub...
|
|
WO/2014/082739A1 |
The invention relates to amino-arylcarboxamides of formula (I), to pharmaceutical compositions containing these compounds and also to these compounds for use In the treatment and/or prophylaxis of pain and further diseases and/or disorders.
|
|
WO/2014/081697A2 |
The present invention relates to novel anthelmintic compounds of formula (I) wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic...
|
|
WO/2014/079850A1 |
The present invention relates to compounds of general formula (I-1) or (I-2) wherein R1 is hydrogen, lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; R1' is hydrogen, lower alkyl, lower alko...
|
|
WO/2014/079354A1 |
Disclosed are acrylonitrile compounds with novel structure or stereoisomers thereof, and the structure of the compounds is as shown by the general formula (I): In the formula: R is selected from C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloa...
|
|
WO/2014/075403A1 |
Disclosed in the present invention are 4-(5-amino-6-hydroxybenzoxazol-2-yl)ammonium benzoate shown in formula (I) and the preparation method and use thereof. The preparation method comprises: fully reacting 4-(5-amino-6-hydroxybenzoxazol...
|
|
WO/2014/078322A1 |
Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment o...
|
|
WO/2014/071990A1 |
The present invention relates to a benzoate salt of the compound 3-(3-fluoro-4- (morpholin-4-yl)phenyl)-2-oxooxazolidin-5(S)-ylmethyl)amine of formula (II-D), which is useful in the purification of the compound of formula (II) and in a p...
|
|
WO/2014/074365A1 |
The present invention provides compounds of Formula I. Wherein Rl, L, and A are as described herein, or a pharmaceutical salt thereof, processes for preparing the compounds, and methods of treating a condition, such as hypertriglyceridem...
|
|
WO/2014/067861A1 |
The invention provides compounds having the general formula I wherein n, R1, R2a, R2b, R3a and R3b are as herein defined., composition comprising the compounds and methods of using the compounds.
|
|
WO/2014/069510A1 |
A novel amine derivative expressed by general formula (1) (in the formula: G1, G2, and G3 are the same or different and represent CH or a nitrogen atom; R1 represents a chlorine atom, an optionally-substituted C3-8 cycloalkyl group, or t...
|
|
WO/2014/066490A1 |
Disclosed are compounds of Formula A: Formula A, or a salt thereof, wherein "Het", Ra, and Rb are defined herein, which have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pha...
|
|
WO/2014/060357A1 |
The present invention relates to novel compounds, having an azlactone function, of formula (I), to be used as multifunctional coupling agents, and to a method for coupling a biomolecule and a target molecule using such a compound. The in...
|
|
WO/2014/063168A1 |
This appl ication describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, wh ich compounds and methods can be used, for example, to med iate h igh-density l ipoprotein (H DL) l ipid uptake an...
|
|
WO/2014/043715A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone...
|
|
WO/2014/040936A1 |
The present invention relates to solid forms of (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl- oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid, and of salts of (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy
]-benzo[b]...
|
|
WO/2014/036623A1 |
The present invention relates to the production of synthetic molecules of N‑substituted chiral aromatic oxazolidines, the process for the synthesis thereof, pharmaceutical compositions containing said molecules and to the use of these ...
|
|
WO/2014/038882A1 |
The present invention relates to a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating STAT3-mediated diseases containing the same as an act...
|
|
WO/2014/037340A1 |
The invention relates to the use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles of general formula (I) or the salts thereof, the groups in general formula (I) corresponding to the definitions cited in...
|
|
WO/2014/034958A1 |
An object of the present invention is to provide a novel method for producing an oxazole compound. The invention relates to a method for producing a compound represented by formula (1): wherein R1 is lower alkyl group or halogen substitu...
|
|
WO/2014/026244A1 |
The present invention relates to photoactive optoelectronic devices, such as organic photovoltaic devices, and transistor devices, and to organic compounds for use in the optoelectronic and transistor devices. The present invention also ...
|
|
WO/2014/025891A1 |
In one aspect, the invention relates to compounds having the formula (I): where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having ne...
|
|
WO/2014/023754A1 |
The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are f...
|
|
WO/2014/020984A1 |
Provided is a photosensitive resin composition which has excellent sensitivity, storage stability and heat-resistant transparency. This photosensitive resin composition contains (A) a polymer component which contains a polymer that satis...
|
|
WO/2014/012935A1 |
The present application relates to novel substituted aminoindane- and aminotetralincarboxylic acids, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases and to the use thereof for producti...
|
